Release

Today’s Research Reports on Trending Tickers: Astrazeneca and Valeant Pharmaceuticals

U.S. markets dropped for the first time in four sessions on Tuesday as comments made by new Federal Reserve Chairman Jerome Powell hinted interest rates could rise more quickly this year. The Dow Jones Industrial declined 1.16 percent to close at 25,410.03, while the S&P 500 Index dropped 1.27 percent to close at 2,744.28. The Nasdaq Composite Index fell 1.23 percent to close at 7,330.35. The yield on the benchmark 10-year Treasury note jumped 5 basis points to 2.915 percent.

“We’ve seen continuing strength in the labor market. We’ve seen some data that will, in my case, add some confidence to my view that inflation is moving up to target. We’ve also seen continued strength around the globe, and we’ve seen fiscal policy become more stimulative,” Powell said in testimony, according to MarketWatch.

RDI Initiates Coverage on:

Astrazeneca PLC
https://rdinvesting.com/news/?ticker=AZN

Valeant Pharmaceuticals Intl Inc.
https://rdinvesting.com/news/?ticker=VRX

Astrazeneca’s stock edged 0.99% lower Tuesday, to close the day at $33.85. The stock recorded a trading volume of 1,982,848 shares, which was below its three months average volume of 3,838,275 shares. In the last year, Astrazeneca’s shares have traded in a range of 28.43 – 36.70. The share price has gained 19.06% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $34.89 is greater than its 200-day moving average of $33.40. Shares of the company are trading at a Price to Earnings ratio of 28.57. Shares of Astrazeneca have fallen roughly 7.59 percent in the past month and are down 2.45 percent year-to-date.  

Access RDI’s Astrazeneca PLC Research Report at:  
https://rdinvesting.com/news/?ticker=AZN

On Tuesday, shares of Valeant Pharmaceuticals recorded a trading volume of 13,106,978 shares, which was below the three months average volume of 16,071,814 shares. The stock ended the day 1.96% lower at 18.50. The share price has gained 122.62% from its 52 week low with a 52 week trading range of 8.31 – 24.43. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $19.92 is greater than its 200-day moving average of $16.59. Shares of Valeant Pharmaceuticals are trading at a Price to Earnings ratio of 4.72. Shares of Valeant Pharmaceuticals have fallen roughly 4.24 percent in the past month and are down 10.97 percent year-to-date.   

Access RDI’s Valeant Pharmaceuticals Intl Inc. Research Report at:  
https://rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Astrazeneca PLC (NYSE:AZN) and Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.